I-06 Orna Amir Predictive Model for Identification of Responders/Non Responders in Metastatic Breast Cancer Patients Treated with Docetaxel Wednesday 10:15-11:45 |
I-15 Brendan Bender A semi-mechanistic population Pharmacokinetic-Pharmacodynamic (PKPD) model of thrombocytopenia characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer Wednesday 10:15-11:45 |
I-21 Michael Block Mechanistic PBPK/PD modeling for prediction of study outcome of cancer therapies: Translating in-vitro information into valid in-vivo predictions Wednesday 10:15-11:45 |
I-23 Guillaume Bonnefois A nonlinear mixed effect model to study albumin-mediated drug transport into endothelial cells in vitro. Wednesday 10:15-11:45 |
I-24 Stephan Borghorst Age Dependent Volume of Distribution of Pegylated Asparaginase (OncasparTM) in children and adults Wednesday 10:15-11:45 |
II-09 Eric Fernandez Using the Virtual Tumour to predict and optimize drug combination regimens Wednesday 14:55-16:10 |
II-14 Gregory Ferl Population analysis of the DCE-MRI response of liver metastases to a single dose of bevacizumab in CRC patients Wednesday 14:55-16:10 |
II-16 Nicolas Frances Integrating distribution to tumor tissue into a dynamic PK/PD model to evaluate the anti-cancer effect of erlotinib in patient-derived LXFA 677 tumor xenograft mice Wednesday 14:55-16:10 |
II-28 Iztok Grabnar Bayesian Estimation of Methotrexate Pharmacokinetics in Children with Acute Lymphoblastic Leukaemia and Prediction of Folinic Acid Rescue Wednesday 14:55-16:10 |
II-31 Joachim Grevel A physiology-based model predicts pharmacokinetics, target occupancy in the tumour, and HSP70 biomarker response in serum for the HSP90 inhibitor, 17-AAG Wednesday 14:55-16:10 |
II-36 Neeraj Gupta Population PK and PK/PD Analysis of Intravenous Investigational Agent MLN9708 in Solid Tumors and Lymphoma Patients Wednesday 14:55-16:10 |
III-04 Steve Kuan Population Pharmacokinetic Modeling of Investigational Agent MLN4924 in Cancer Patients Thursday 09:50-11:05 |
III-17 Paolo Magni A new population PK/PD model to assess the myelotoxicity of candidate drugs in preclinical and in clinical studies Thursday 09:50-11:05 |
III-21 Maria Matoses Osborne Ex Vivo modeling of the apoptotic effects of Vivia009 and its metabolite in patients with Chronic Lymphocytic Leukemia Thursday 09:50-11:05 |
III-30 Daniele Morpurgo Predicting the Gemcitabine efficacy by a stochastic language based model Thursday 09:50-11:05 |
III-34 Ronald Niebecker Importance of study design for estimation of Vmax and Km characterising nonlinear monoclonal antibody clearance Thursday 09:50-11:05 |
III-37 Valerie Nock Leukopenia following triple high-dose chemotherapy and stem cell rescue Thursday 09:50-11:05 |
III-50 Kirill Peskov Systems Modeling of EphB4/ephrinB2 Signaling Pathways Thursday 09:50-11:05 |
IV-03 Franziska Schädeli Stark A semi-mechanistic population pharmacokinetic model for trastuzumab emtansine (T-DM1) antibody-drug conjugate and total antibody in patients with metastatic breast cancer (mBC) Thursday 15:05-16:20 |
IV-11 Alexandre Sostelly Characterization of the interaction between irinotecan, SN-38 and MBLI-87, a new BCRP inhibitor, with a multi-scale semi-mechanistic PKPD model Thursday 15:05-16:20 |
IV-27 Mirjam Trame Busulfan Dosing in Children: Body Weight versus Body Surface Area or Allometric Body Weight Dosing Thursday 15:05-16:20 |
IV-50 Mélanie Wilbaux Population K-PD modeling of CA125 and tumor size kinetics in relapsed ovarian cancer patients Thursday 15:05-16:20 |
IV-58 James Yates Characterisation of Xenograft Response to Docetaxel by Nonlinear Mixed Effects Modelling Thursday 15:05-16:20 |
IV-63 Jianping Zhang Population Pharmacokinetics of Lapatinib in Cancer Patients Thursday 15:05-16:20 |